Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 10Thoracic 2Sarcoma 2Gynecologic 2Gastrointestinal 2Dermatologic 2Lymphoid 1Head & Neck 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma 23Burkitt Lymphoma 22Multiple Myeloma 20Lymphoma, Non-Hodgkin 17Leukemia, Myeloid, Acute 16Lymphoma, Follicular 15Myelodysplastic Syndromes 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell 13Leukemia, Biphenotypic, Acute 13Lymphoma, T-Cell 9Hodgkin Disease 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Neuroblastoma 7Lymphoma, B-Cell, Marginal Zone 7Glioma 7Wilms Tumor 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Central Nervous System Neoplasms 6Rhabdoid Tumor 5Primary Myelofibrosis 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Myeloproliferative Disorders 5Mycosis Fungoides 5

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Specimen Handling × Lymphoid × Clear all
NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡